Lucentis approved in Japan

Article

Lucentis (ranibizumab; Novartis) has been approved for the treatment of wet age-related macular degeneration (AMD) in Japan, Novartis has announced.

Lucentis (ranibizumab; Novartis) has been approved for the treatment of wet age-related macular degeneration (AMD) in Japan, Novartis has announced.

The application for approval in Japan was supported by a clinical trial demonstrating the efficacy of the anti-vascular endothelial growth factor (anti-VEGF) therapy. The approval comes simultaneously with three other Novartis drug approvals in Japan: Tasigna, for cancer, Xolair for asthma and Co-Dio for high blood pressure.

Lucentis has been approved in Europe since February 2007.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Related Content
© 2025 MJH Life Sciences

All rights reserved.